AZD1480 is another inhibitor of JAK1 and JAK2, which effectively inhibited IL-6/STAT3-driven metastasis in vivo [184] and was investigated in a phase I study to assess the safety and tolerability of AZD1480 in 38 patients with advanced solid malignancies, including PCa. Here, STAT3 is linked to posterior cortical atrophy.